Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma

[1]  J. Cerhan,et al.  Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. , 2010, American journal of epidemiology.

[2]  Y. Wang,et al.  Kank proteins: structure, functions and diseases , 2009, Cellular and Molecular Life Sciences.

[3]  J. Schlessinger,et al.  Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization , 2008, Proceedings of the National Academy of Sciences.

[4]  F. Grand,et al.  A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease , 2007, Leukemia.

[5]  G. Salles,et al.  Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non‐Hodgkin's lymphoma , 2007, Genes, chromosomes & cancer.

[6]  Nilanjan Chatterjee,et al.  Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. , 2006, Cancer research.

[7]  I. Lerer,et al.  Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy. , 2005, Human molecular genetics.

[8]  G. Assmann,et al.  Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA‐DR3 , 2005, Scandinavian journal of rheumatology.

[9]  A. Jones,et al.  Oncogenic derivatives of platelet-derived growth factor receptors. , 2004, Cellular and molecular life sciences : CMLS.

[10]  D. Kwiatkowski,et al.  Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[11]  G. Salles,et al.  Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. , 2002, Blood.

[12]  C. Caruso,et al.  Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. , 2002, Autoimmunity reviews.

[13]  Jerzy K. Kulski,et al.  The HLA genomic loci map: expression, interaction, diversity and disease , 2009, Journal of Human Genetics.

[14]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[15]  J. Melo,et al.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.

[16]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[17]  M. Cazzola,et al.  Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V 617 F mutation of Jak 2 , 2005 .